Albert Robichaud, Chief Scientific Officer at Sage Therapeutics, Inc. (SAGE), sold 16,000 shares at $72.93 ($1.2M) on 2015-06-01, disclosed to the SEC on 2015-06-02.
Scheduled sale ($1.2M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $71.21 | 200 | $14K | 1.2% |
| 2 | $71.67 | 5,231 | $375K | 32.2% |
| 3 | $72.93 | 5,624 | $410K | 35.2% |
| 4 | $73.89 | 4,945 | $365K | 31.4% |
| Total | $72.79 avg | 16,000 | $1.2M | 100% |
| Filing → |
| SAGE | SELL | 2016-07-14 | $880K | — | Filing → |
| SAGE | SELL | 2016-01-26 | $1.6M | — | Filing → |
| SAGE | SELL | 2015-08-04 | $805K | — | Filing → |